Inovio Pharmaceuticals (INO) Stock
Clinical stage biotech developing DNA vaccines and immunotherapies. Here's the price, business snapshot, and what's worth knowing about Inovio Pharmaceuticals in October 2026.
Inovio Pharmaceuticals (INO) is a clinical‑stage biotechnology company developing DNA‑based vaccines and immunotherapies, using a proprietary electroporation delivery platform. Investors should know it is small‑cap and research‑driven: value is tied to clinical trial readouts, regulatory progress and partnerships rather than stable revenues. The company’s pipeline targets infectious diseases and oncology, and progress often comes in discrete, binary milestones that can cause sharp share‑price moves. As a small biopharma, Inovio may need to raise capital from time to time, which can dilute shareholders. Key considerations for investors include the stage and quality of clinical data, cash runway, partner relationships and the competitive landscape for vaccine and immunotherapy technologies. This summary is educational and not personalised advice — biotech investing carries elevated risk and potential volatility, and past developments are not a reliable guide to future results.
Inovio Pharmaceuticals (INO) Stock Forecast
Analyst price target, next 12 months
$8.81
+882.3% vs today's $0.90
Price range over the last 12 months
Close to its 12-month low
Analysts covering Inovio Pharmaceuticals have a consensus 12-month target of $8.81, above the current price of $0.90.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 24 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying INOVIO's stock, with a target price of $8.81, indicating significant growth potential.
Financial Health
INOVIO Pharmaceuticals has low book value and cash flow, indicating financial challenges ahead.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical Catalysts Ahead
Pipeline trial readouts and regulatory steps can meaningfully move the share price; however, outcomes are binary and can be volatile.
Platform Innovation
The DNA electroporation approach is central to Inovio’s strategy and may offer differentiation, yet scientific and competitive risk remains.
Funding And Runway
Small‑cap status means funding rounds are possible and can dilute existing holders; monitor cash reports and partnership deals.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
